RUBICON RESEARCH LIMITED
NSE: RUBICONMarket Closed • NSE
Day range
52 week range
RUBICON RESEARCH LIMITED closed at INR1548.50 (+0.85%) on volume 0.59x its 20-day average, trading 18.46% below its 52-week high.
2026-Q2
Q2 FY2026 Financial Results
PAT moved +10.4% QoQ
2026-08-07
DIVIDEND Announced
Dividend - Rs 1.50 Per Share
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Strong Capital Efficiency: ROCE stands at 28.4%
Low Debt Profile: Debt-to-Equity is comfortable at 0.24x
Risks
Stretched Valuation: Trading at a high P/E multiple of 89.2x
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - General.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Ownership distribution
Category trends
Hover over a period for exact holdings
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 07 Aug 2026 | Dividend | ₹1.50 / share | — | 07 Aug 2026 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.92 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.48L | 84.75 | 0.32% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.77L | 74.39 | 0.82% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.17L | 183.15 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.15L | 55.26 | 0.26% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.11L | 24.91 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.10L | 100.67 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.05L | 31.20 | 0.99% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Incorporated in 1999, Rubicon Research Limited is a pharmaceutical company engaged in the development, manufacturing, & commercialization of differentiated formulations.[1]
IndiaHealthcare
Is RUBICON RESEARCH LIMITED Shariah compliant?
RUBICON RESEARCH LIMITED is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (1.21%) complies with AAOIFI threshold (≤ 33%).
What is RUBICON RESEARCH LIMITED's current valuation relative to peers?
RUBICON RESEARCH LIMITED trades at a P/E of 89.2x compared to the sector median of 37.6x, and a Price-to-Book of 19.8x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.24x and a Net Debt to EBITDA ratio of 0.78x. Interest coverage is 9.5x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at 34.8% while net profit growth averaged consistent levels.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-09. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.